Global Batten Disease Treatment Market
Global Batten Disease Treatment Market

Batten Disease Treatment Comprehensive Study by Disease Type (Juvenile NCL, Infantile NCL, Late infantile NCL, Adult NCL), Route of Administration (Oral, Parenteral), Therapy Type (Occupational Therapy, Physical Therapy), End-Users (Hospitals, Homecare, Specialty Clinics, Others) Players and Region - Global Market Outlook to 2025

Batten Disease Treatment Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Dec 2020 Edition 220 Pages 212 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Batten Disease Treatment Market Overview:
Batten Disease Treatment is used to treat a genetic disorder that is caused by autosomal recessive genetic mutation mainly occur in childhood. As per sources, the prevalence of juvenile CLN disease is equal in males and females. In the United States, the occurrence of neuronal ceroid lipofuscinoses is approximately three in 100,000 births and one in 25,000 infants in northern Europe. The growing occurrences of diseases and clinical trials will boost the market growth in the coming years. Some of the players profiled in the study are BioMarin Pharmaceutical Inc. (United States), Seneb BioSciences, Inc. (United States), ReGenX Biosciences LLC (United States), Amicus Therapeutics (United States), Ionis Pharmaceuticals, Inc. (United States), Celenex, Inc. (United States), Pfizer Inc (United States), Polaryx Therapeutics, Inc (United States), Abeona Therapeutics Inc (United States) and Evotec SE (Germany).

On the basis of geography, the market of Batten Disease Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2019. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. If we see Market by Disease Type, the sub-segment i.e. Juvenile NCL will boost the Batten Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the Batten Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Therapy Type, the sub-segment i.e. Occupational Therapy will boost the Batten Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-Users, the sub-segment i.e. Hospitals will boost the Batten Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers
  • Growing Prevalence Of Neurological Disorders
  • Increasing Investment In Research & Development By Biotechnology And Pharmaceutical Industries

Influencing Trend
  • Need For The Better Treatment Methods

Restraints
  • High Cost Of Treatment

Opportunities
  • Growing Global Healthcare Expenditure Is Also Enhancing This Market Growth
  • Rising Need For The Better Treatment Methods

Challenges
  • Lacking Of Healthcare Professional For Physical Therapy


Key Market Developments:


In April 2020, Polaryx Therapeutics received an Investigational New Drug Application (IND) approval from the U.S. Food and Drug Administration (FDA) to study PLX-200 treatment on Juvenile Neuronal Ceroid Lipofuscinosis (JNCL or CLN3) patients.

Target Audience:
New Entrants/Investors, Analysts and Strategic Business Planners, Batten Disease Treatment Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End Use Industry

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Batten Disease Treatment market on the basis of product [] , application [], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Batten Disease Treatment market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Batten Disease Treatment industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Spark Therapeutics, Inc (United States), Regenxbio Inc (United States), BioMarin Pharmaceutical Inc. (United States), STEMCELL Technologies Inc. (Canada) and Neurogene Inc. (United States).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Batten Disease Treatment market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Report Objectives / Segmentation Covered
By Disease Type
  • Juvenile NCL
  • Infantile NCL
  • Late infantile NCL
  • Adult NCL

By Route of Administration
  • Oral
  • Parenteral

By Therapy Type
  • Occupational Therapy
  • Physical Therapy

By End-Users
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence Of Neurological Disorders
      • 3.2.2. Increasing Investment In Research & Development By Biotechnology And Pharmaceutical Industries
    • 3.3. Market Challenges
      • 3.3.1. Lacking Of Healthcare Professional For Physical Therapy
    • 3.4. Market Trends
      • 3.4.1. Need For The Better Treatment Methods
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Batten Disease Treatment, by Disease Type, Route of Administration, Therapy Type, End-Users and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Batten Disease Treatment (Value)
      • 5.2.1. Global Batten Disease Treatment by: Disease Type (Value)
        • 5.2.1.1. Juvenile NCL
        • 5.2.1.2. Infantile NCL
        • 5.2.1.3. Late infantile NCL
        • 5.2.1.4. Adult NCL
      • 5.2.2. Global Batten Disease Treatment by: Route of Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Parenteral
      • 5.2.3. Global Batten Disease Treatment by: Therapy Type (Value)
        • 5.2.3.1. Occupational Therapy
        • 5.2.3.2. Physical Therapy
      • 5.2.4. Global Batten Disease Treatment by: End-Users (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Homecare
        • 5.2.4.3. Specialty Clinics
        • 5.2.4.4. Others
      • 5.2.5. Global Batten Disease Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Batten Disease Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. BioMarin Pharmaceutical Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Seneb BioSciences, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. ReGenX Biosciences LLC (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Amicus Therapeutics (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Ionis Pharmaceuticals, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Celenex, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer Inc (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Polaryx Therapeutics, Inc (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Abeona Therapeutics Inc (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Evotec SE (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Batten Disease Treatment Sale, by Disease Type, Route of Administration, Therapy Type, End-Users and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Batten Disease Treatment (Value)
      • 7.2.1. Global Batten Disease Treatment by: Disease Type (Value)
        • 7.2.1.1. Juvenile NCL
        • 7.2.1.2. Infantile NCL
        • 7.2.1.3. Late infantile NCL
        • 7.2.1.4. Adult NCL
      • 7.2.2. Global Batten Disease Treatment by: Route of Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Parenteral
      • 7.2.3. Global Batten Disease Treatment by: Therapy Type (Value)
        • 7.2.3.1. Occupational Therapy
        • 7.2.3.2. Physical Therapy
      • 7.2.4. Global Batten Disease Treatment by: End-Users (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Homecare
        • 7.2.4.3. Specialty Clinics
        • 7.2.4.4. Others
      • 7.2.5. Global Batten Disease Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Batten Disease Treatment: by Disease Type(USD Million)
  • Table 2. Batten Disease Treatment Juvenile NCL , by Region USD Million (2014-2019)
  • Table 3. Batten Disease Treatment Infantile NCL , by Region USD Million (2014-2019)
  • Table 4. Batten Disease Treatment Late infantile NCL , by Region USD Million (2014-2019)
  • Table 5. Batten Disease Treatment Adult NCL , by Region USD Million (2014-2019)
  • Table 6. Batten Disease Treatment: by Route of Administration(USD Million)
  • Table 7. Batten Disease Treatment Oral , by Region USD Million (2014-2019)
  • Table 8. Batten Disease Treatment Parenteral , by Region USD Million (2014-2019)
  • Table 9. Batten Disease Treatment: by Therapy Type(USD Million)
  • Table 10. Batten Disease Treatment Occupational Therapy , by Region USD Million (2014-2019)
  • Table 11. Batten Disease Treatment Physical Therapy , by Region USD Million (2014-2019)
  • Table 12. Batten Disease Treatment: by End-Users(USD Million)
  • Table 13. Batten Disease Treatment Hospitals , by Region USD Million (2014-2019)
  • Table 14. Batten Disease Treatment Homecare , by Region USD Million (2014-2019)
  • Table 15. Batten Disease Treatment Specialty Clinics , by Region USD Million (2014-2019)
  • Table 16. Batten Disease Treatment Others , by Region USD Million (2014-2019)
  • Table 17. South America Batten Disease Treatment, by Country USD Million (2014-2019)
  • Table 18. South America Batten Disease Treatment, by Disease Type USD Million (2014-2019)
  • Table 19. South America Batten Disease Treatment, by Route of Administration USD Million (2014-2019)
  • Table 20. South America Batten Disease Treatment, by Therapy Type USD Million (2014-2019)
  • Table 21. South America Batten Disease Treatment, by End-Users USD Million (2014-2019)
  • Table 22. Brazil Batten Disease Treatment, by Disease Type USD Million (2014-2019)
  • Table 23. Brazil Batten Disease Treatment, by Route of Administration USD Million (2014-2019)
  • Table 24. Brazil Batten Disease Treatment, by Therapy Type USD Million (2014-2019)
  • Table 25. Brazil Batten Disease Treatment, by End-Users USD Million (2014-2019)
  • Table 26. Argentina Batten Disease Treatment, by Disease Type USD Million (2014-2019)
  • Table 27. Argentina Batten Disease Treatment, by Route of Administration USD Million (2014-2019)
  • Table 28. Argentina Batten Disease Treatment, by Therapy Type USD Million (2014-2019)
  • Table 29. Argentina Batten Disease Treatment, by End-Users USD Million (2014-2019)
  • Table 30. Rest of South America Batten Disease Treatment, by Disease Type USD Million (2014-2019)
  • Table 31. Rest of South America Batten Disease Treatment, by Route of Administration USD Million (2014-2019)
  • Table 32. Rest of South America Batten Disease Treatment, by Therapy Type USD Million (2014-2019)
  • Table 33. Rest of South America Batten Disease Treatment, by End-Users USD Million (2014-2019)
  • Table 34. Asia Pacific Batten Disease Treatment, by Country USD Million (2014-2019)
  • Table 35. Asia Pacific Batten Disease Treatment, by Disease Type USD Million (2014-2019)
  • Table 36. Asia Pacific Batten Disease Treatment, by Route of Administration USD Million (2014-2019)
  • Table 37. Asia Pacific Batten Disease Treatment, by Therapy Type USD Million (2014-2019)
  • Table 38. Asia Pacific Batten Disease Treatment, by End-Users USD Million (2014-2019)
  • Table 39. China Batten Disease Treatment, by Disease Type USD Million (2014-2019)
  • Table 40. China Batten Disease Treatment, by Route of Administration USD Million (2014-2019)
  • Table 41. China Batten Disease Treatment, by Therapy Type USD Million (2014-2019)
  • Table 42. China Batten Disease Treatment, by End-Users USD Million (2014-2019)
  • Table 43. Japan Batten Disease Treatment, by Disease Type USD Million (2014-2019)
  • Table 44. Japan Batten Disease Treatment, by Route of Administration USD Million (2014-2019)
  • Table 45. Japan Batten Disease Treatment, by Therapy Type USD Million (2014-2019)
  • Table 46. Japan Batten Disease Treatment, by End-Users USD Million (2014-2019)
  • Table 47. India Batten Disease Treatment, by Disease Type USD Million (2014-2019)
  • Table 48. India Batten Disease Treatment, by Route of Administration USD Million (2014-2019)
  • Table 49. India Batten Disease Treatment, by Therapy Type USD Million (2014-2019)
  • Table 50. India Batten Disease Treatment, by End-Users USD Million (2014-2019)
  • Table 51. South Korea Batten Disease Treatment, by Disease Type USD Million (2014-2019)
  • Table 52. South Korea Batten Disease Treatment, by Route of Administration USD Million (2014-2019)
  • Table 53. South Korea Batten Disease Treatment, by Therapy Type USD Million (2014-2019)
  • Table 54. South Korea Batten Disease Treatment, by End-Users USD Million (2014-2019)
  • Table 55. Taiwan Batten Disease Treatment, by Disease Type USD Million (2014-2019)
  • Table 56. Taiwan Batten Disease Treatment, by Route of Administration USD Million (2014-2019)
  • Table 57. Taiwan Batten Disease Treatment, by Therapy Type USD Million (2014-2019)
  • Table 58. Taiwan Batten Disease Treatment, by End-Users USD Million (2014-2019)
  • Table 59. Australia Batten Disease Treatment, by Disease Type USD Million (2014-2019)
  • Table 60. Australia Batten Disease Treatment, by Route of Administration USD Million (2014-2019)
  • Table 61. Australia Batten Disease Treatment, by Therapy Type USD Million (2014-2019)
  • Table 62. Australia Batten Disease Treatment, by End-Users USD Million (2014-2019)
  • Table 63. Rest of Asia-Pacific Batten Disease Treatment, by Disease Type USD Million (2014-2019)
  • Table 64. Rest of Asia-Pacific Batten Disease Treatment, by Route of Administration USD Million (2014-2019)
  • Table 65. Rest of Asia-Pacific Batten Disease Treatment, by Therapy Type USD Million (2014-2019)
  • Table 66. Rest of Asia-Pacific Batten Disease Treatment, by End-Users USD Million (2014-2019)
  • Table 67. Europe Batten Disease Treatment, by Country USD Million (2014-2019)
  • Table 68. Europe Batten Disease Treatment, by Disease Type USD Million (2014-2019)
  • Table 69. Europe Batten Disease Treatment, by Route of Administration USD Million (2014-2019)
  • Table 70. Europe Batten Disease Treatment, by Therapy Type USD Million (2014-2019)
  • Table 71. Europe Batten Disease Treatment, by End-Users USD Million (2014-2019)
  • Table 72. Germany Batten Disease Treatment, by Disease Type USD Million (2014-2019)
  • Table 73. Germany Batten Disease Treatment, by Route of Administration USD Million (2014-2019)
  • Table 74. Germany Batten Disease Treatment, by Therapy Type USD Million (2014-2019)
  • Table 75. Germany Batten Disease Treatment, by End-Users USD Million (2014-2019)
  • Table 76. France Batten Disease Treatment, by Disease Type USD Million (2014-2019)
  • Table 77. France Batten Disease Treatment, by Route of Administration USD Million (2014-2019)
  • Table 78. France Batten Disease Treatment, by Therapy Type USD Million (2014-2019)
  • Table 79. France Batten Disease Treatment, by End-Users USD Million (2014-2019)
  • Table 80. Italy Batten Disease Treatment, by Disease Type USD Million (2014-2019)
  • Table 81. Italy Batten Disease Treatment, by Route of Administration USD Million (2014-2019)
  • Table 82. Italy Batten Disease Treatment, by Therapy Type USD Million (2014-2019)
  • Table 83. Italy Batten Disease Treatment, by End-Users USD Million (2014-2019)
  • Table 84. United Kingdom Batten Disease Treatment, by Disease Type USD Million (2014-2019)
  • Table 85. United Kingdom Batten Disease Treatment, by Route of Administration USD Million (2014-2019)
  • Table 86. United Kingdom Batten Disease Treatment, by Therapy Type USD Million (2014-2019)
  • Table 87. United Kingdom Batten Disease Treatment, by End-Users USD Million (2014-2019)
  • Table 88. Netherlands Batten Disease Treatment, by Disease Type USD Million (2014-2019)
  • Table 89. Netherlands Batten Disease Treatment, by Route of Administration USD Million (2014-2019)
  • Table 90. Netherlands Batten Disease Treatment, by Therapy Type USD Million (2014-2019)
  • Table 91. Netherlands Batten Disease Treatment, by End-Users USD Million (2014-2019)
  • Table 92. Rest of Europe Batten Disease Treatment, by Disease Type USD Million (2014-2019)
  • Table 93. Rest of Europe Batten Disease Treatment, by Route of Administration USD Million (2014-2019)
  • Table 94. Rest of Europe Batten Disease Treatment, by Therapy Type USD Million (2014-2019)
  • Table 95. Rest of Europe Batten Disease Treatment, by End-Users USD Million (2014-2019)
  • Table 96. MEA Batten Disease Treatment, by Country USD Million (2014-2019)
  • Table 97. MEA Batten Disease Treatment, by Disease Type USD Million (2014-2019)
  • Table 98. MEA Batten Disease Treatment, by Route of Administration USD Million (2014-2019)
  • Table 99. MEA Batten Disease Treatment, by Therapy Type USD Million (2014-2019)
  • Table 100. MEA Batten Disease Treatment, by End-Users USD Million (2014-2019)
  • Table 101. Middle East Batten Disease Treatment, by Disease Type USD Million (2014-2019)
  • Table 102. Middle East Batten Disease Treatment, by Route of Administration USD Million (2014-2019)
  • Table 103. Middle East Batten Disease Treatment, by Therapy Type USD Million (2014-2019)
  • Table 104. Middle East Batten Disease Treatment, by End-Users USD Million (2014-2019)
  • Table 105. Africa Batten Disease Treatment, by Disease Type USD Million (2014-2019)
  • Table 106. Africa Batten Disease Treatment, by Route of Administration USD Million (2014-2019)
  • Table 107. Africa Batten Disease Treatment, by Therapy Type USD Million (2014-2019)
  • Table 108. Africa Batten Disease Treatment, by End-Users USD Million (2014-2019)
  • Table 109. North America Batten Disease Treatment, by Country USD Million (2014-2019)
  • Table 110. North America Batten Disease Treatment, by Disease Type USD Million (2014-2019)
  • Table 111. North America Batten Disease Treatment, by Route of Administration USD Million (2014-2019)
  • Table 112. North America Batten Disease Treatment, by Therapy Type USD Million (2014-2019)
  • Table 113. North America Batten Disease Treatment, by End-Users USD Million (2014-2019)
  • Table 114. United States Batten Disease Treatment, by Disease Type USD Million (2014-2019)
  • Table 115. United States Batten Disease Treatment, by Route of Administration USD Million (2014-2019)
  • Table 116. United States Batten Disease Treatment, by Therapy Type USD Million (2014-2019)
  • Table 117. United States Batten Disease Treatment, by End-Users USD Million (2014-2019)
  • Table 118. Canada Batten Disease Treatment, by Disease Type USD Million (2014-2019)
  • Table 119. Canada Batten Disease Treatment, by Route of Administration USD Million (2014-2019)
  • Table 120. Canada Batten Disease Treatment, by Therapy Type USD Million (2014-2019)
  • Table 121. Canada Batten Disease Treatment, by End-Users USD Million (2014-2019)
  • Table 122. Mexico Batten Disease Treatment, by Disease Type USD Million (2014-2019)
  • Table 123. Mexico Batten Disease Treatment, by Route of Administration USD Million (2014-2019)
  • Table 124. Mexico Batten Disease Treatment, by Therapy Type USD Million (2014-2019)
  • Table 125. Mexico Batten Disease Treatment, by End-Users USD Million (2014-2019)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Batten Disease Treatment: by Disease Type(USD Million)
  • Table 137. Batten Disease Treatment Juvenile NCL , by Region USD Million (2020-2025)
  • Table 138. Batten Disease Treatment Infantile NCL , by Region USD Million (2020-2025)
  • Table 139. Batten Disease Treatment Late infantile NCL , by Region USD Million (2020-2025)
  • Table 140. Batten Disease Treatment Adult NCL , by Region USD Million (2020-2025)
  • Table 141. Batten Disease Treatment: by Route of Administration(USD Million)
  • Table 142. Batten Disease Treatment Oral , by Region USD Million (2020-2025)
  • Table 143. Batten Disease Treatment Parenteral , by Region USD Million (2020-2025)
  • Table 144. Batten Disease Treatment: by Therapy Type(USD Million)
  • Table 145. Batten Disease Treatment Occupational Therapy , by Region USD Million (2020-2025)
  • Table 146. Batten Disease Treatment Physical Therapy , by Region USD Million (2020-2025)
  • Table 147. Batten Disease Treatment: by End-Users(USD Million)
  • Table 148. Batten Disease Treatment Hospitals , by Region USD Million (2020-2025)
  • Table 149. Batten Disease Treatment Homecare , by Region USD Million (2020-2025)
  • Table 150. Batten Disease Treatment Specialty Clinics , by Region USD Million (2020-2025)
  • Table 151. Batten Disease Treatment Others , by Region USD Million (2020-2025)
  • Table 152. South America Batten Disease Treatment, by Country USD Million (2020-2025)
  • Table 153. South America Batten Disease Treatment, by Disease Type USD Million (2020-2025)
  • Table 154. South America Batten Disease Treatment, by Route of Administration USD Million (2020-2025)
  • Table 155. South America Batten Disease Treatment, by Therapy Type USD Million (2020-2025)
  • Table 156. South America Batten Disease Treatment, by End-Users USD Million (2020-2025)
  • Table 157. Brazil Batten Disease Treatment, by Disease Type USD Million (2020-2025)
  • Table 158. Brazil Batten Disease Treatment, by Route of Administration USD Million (2020-2025)
  • Table 159. Brazil Batten Disease Treatment, by Therapy Type USD Million (2020-2025)
  • Table 160. Brazil Batten Disease Treatment, by End-Users USD Million (2020-2025)
  • Table 161. Argentina Batten Disease Treatment, by Disease Type USD Million (2020-2025)
  • Table 162. Argentina Batten Disease Treatment, by Route of Administration USD Million (2020-2025)
  • Table 163. Argentina Batten Disease Treatment, by Therapy Type USD Million (2020-2025)
  • Table 164. Argentina Batten Disease Treatment, by End-Users USD Million (2020-2025)
  • Table 165. Rest of South America Batten Disease Treatment, by Disease Type USD Million (2020-2025)
  • Table 166. Rest of South America Batten Disease Treatment, by Route of Administration USD Million (2020-2025)
  • Table 167. Rest of South America Batten Disease Treatment, by Therapy Type USD Million (2020-2025)
  • Table 168. Rest of South America Batten Disease Treatment, by End-Users USD Million (2020-2025)
  • Table 169. Asia Pacific Batten Disease Treatment, by Country USD Million (2020-2025)
  • Table 170. Asia Pacific Batten Disease Treatment, by Disease Type USD Million (2020-2025)
  • Table 171. Asia Pacific Batten Disease Treatment, by Route of Administration USD Million (2020-2025)
  • Table 172. Asia Pacific Batten Disease Treatment, by Therapy Type USD Million (2020-2025)
  • Table 173. Asia Pacific Batten Disease Treatment, by End-Users USD Million (2020-2025)
  • Table 174. China Batten Disease Treatment, by Disease Type USD Million (2020-2025)
  • Table 175. China Batten Disease Treatment, by Route of Administration USD Million (2020-2025)
  • Table 176. China Batten Disease Treatment, by Therapy Type USD Million (2020-2025)
  • Table 177. China Batten Disease Treatment, by End-Users USD Million (2020-2025)
  • Table 178. Japan Batten Disease Treatment, by Disease Type USD Million (2020-2025)
  • Table 179. Japan Batten Disease Treatment, by Route of Administration USD Million (2020-2025)
  • Table 180. Japan Batten Disease Treatment, by Therapy Type USD Million (2020-2025)
  • Table 181. Japan Batten Disease Treatment, by End-Users USD Million (2020-2025)
  • Table 182. India Batten Disease Treatment, by Disease Type USD Million (2020-2025)
  • Table 183. India Batten Disease Treatment, by Route of Administration USD Million (2020-2025)
  • Table 184. India Batten Disease Treatment, by Therapy Type USD Million (2020-2025)
  • Table 185. India Batten Disease Treatment, by End-Users USD Million (2020-2025)
  • Table 186. South Korea Batten Disease Treatment, by Disease Type USD Million (2020-2025)
  • Table 187. South Korea Batten Disease Treatment, by Route of Administration USD Million (2020-2025)
  • Table 188. South Korea Batten Disease Treatment, by Therapy Type USD Million (2020-2025)
  • Table 189. South Korea Batten Disease Treatment, by End-Users USD Million (2020-2025)
  • Table 190. Taiwan Batten Disease Treatment, by Disease Type USD Million (2020-2025)
  • Table 191. Taiwan Batten Disease Treatment, by Route of Administration USD Million (2020-2025)
  • Table 192. Taiwan Batten Disease Treatment, by Therapy Type USD Million (2020-2025)
  • Table 193. Taiwan Batten Disease Treatment, by End-Users USD Million (2020-2025)
  • Table 194. Australia Batten Disease Treatment, by Disease Type USD Million (2020-2025)
  • Table 195. Australia Batten Disease Treatment, by Route of Administration USD Million (2020-2025)
  • Table 196. Australia Batten Disease Treatment, by Therapy Type USD Million (2020-2025)
  • Table 197. Australia Batten Disease Treatment, by End-Users USD Million (2020-2025)
  • Table 198. Rest of Asia-Pacific Batten Disease Treatment, by Disease Type USD Million (2020-2025)
  • Table 199. Rest of Asia-Pacific Batten Disease Treatment, by Route of Administration USD Million (2020-2025)
  • Table 200. Rest of Asia-Pacific Batten Disease Treatment, by Therapy Type USD Million (2020-2025)
  • Table 201. Rest of Asia-Pacific Batten Disease Treatment, by End-Users USD Million (2020-2025)
  • Table 202. Europe Batten Disease Treatment, by Country USD Million (2020-2025)
  • Table 203. Europe Batten Disease Treatment, by Disease Type USD Million (2020-2025)
  • Table 204. Europe Batten Disease Treatment, by Route of Administration USD Million (2020-2025)
  • Table 205. Europe Batten Disease Treatment, by Therapy Type USD Million (2020-2025)
  • Table 206. Europe Batten Disease Treatment, by End-Users USD Million (2020-2025)
  • Table 207. Germany Batten Disease Treatment, by Disease Type USD Million (2020-2025)
  • Table 208. Germany Batten Disease Treatment, by Route of Administration USD Million (2020-2025)
  • Table 209. Germany Batten Disease Treatment, by Therapy Type USD Million (2020-2025)
  • Table 210. Germany Batten Disease Treatment, by End-Users USD Million (2020-2025)
  • Table 211. France Batten Disease Treatment, by Disease Type USD Million (2020-2025)
  • Table 212. France Batten Disease Treatment, by Route of Administration USD Million (2020-2025)
  • Table 213. France Batten Disease Treatment, by Therapy Type USD Million (2020-2025)
  • Table 214. France Batten Disease Treatment, by End-Users USD Million (2020-2025)
  • Table 215. Italy Batten Disease Treatment, by Disease Type USD Million (2020-2025)
  • Table 216. Italy Batten Disease Treatment, by Route of Administration USD Million (2020-2025)
  • Table 217. Italy Batten Disease Treatment, by Therapy Type USD Million (2020-2025)
  • Table 218. Italy Batten Disease Treatment, by End-Users USD Million (2020-2025)
  • Table 219. United Kingdom Batten Disease Treatment, by Disease Type USD Million (2020-2025)
  • Table 220. United Kingdom Batten Disease Treatment, by Route of Administration USD Million (2020-2025)
  • Table 221. United Kingdom Batten Disease Treatment, by Therapy Type USD Million (2020-2025)
  • Table 222. United Kingdom Batten Disease Treatment, by End-Users USD Million (2020-2025)
  • Table 223. Netherlands Batten Disease Treatment, by Disease Type USD Million (2020-2025)
  • Table 224. Netherlands Batten Disease Treatment, by Route of Administration USD Million (2020-2025)
  • Table 225. Netherlands Batten Disease Treatment, by Therapy Type USD Million (2020-2025)
  • Table 226. Netherlands Batten Disease Treatment, by End-Users USD Million (2020-2025)
  • Table 227. Rest of Europe Batten Disease Treatment, by Disease Type USD Million (2020-2025)
  • Table 228. Rest of Europe Batten Disease Treatment, by Route of Administration USD Million (2020-2025)
  • Table 229. Rest of Europe Batten Disease Treatment, by Therapy Type USD Million (2020-2025)
  • Table 230. Rest of Europe Batten Disease Treatment, by End-Users USD Million (2020-2025)
  • Table 231. MEA Batten Disease Treatment, by Country USD Million (2020-2025)
  • Table 232. MEA Batten Disease Treatment, by Disease Type USD Million (2020-2025)
  • Table 233. MEA Batten Disease Treatment, by Route of Administration USD Million (2020-2025)
  • Table 234. MEA Batten Disease Treatment, by Therapy Type USD Million (2020-2025)
  • Table 235. MEA Batten Disease Treatment, by End-Users USD Million (2020-2025)
  • Table 236. Middle East Batten Disease Treatment, by Disease Type USD Million (2020-2025)
  • Table 237. Middle East Batten Disease Treatment, by Route of Administration USD Million (2020-2025)
  • Table 238. Middle East Batten Disease Treatment, by Therapy Type USD Million (2020-2025)
  • Table 239. Middle East Batten Disease Treatment, by End-Users USD Million (2020-2025)
  • Table 240. Africa Batten Disease Treatment, by Disease Type USD Million (2020-2025)
  • Table 241. Africa Batten Disease Treatment, by Route of Administration USD Million (2020-2025)
  • Table 242. Africa Batten Disease Treatment, by Therapy Type USD Million (2020-2025)
  • Table 243. Africa Batten Disease Treatment, by End-Users USD Million (2020-2025)
  • Table 244. North America Batten Disease Treatment, by Country USD Million (2020-2025)
  • Table 245. North America Batten Disease Treatment, by Disease Type USD Million (2020-2025)
  • Table 246. North America Batten Disease Treatment, by Route of Administration USD Million (2020-2025)
  • Table 247. North America Batten Disease Treatment, by Therapy Type USD Million (2020-2025)
  • Table 248. North America Batten Disease Treatment, by End-Users USD Million (2020-2025)
  • Table 249. United States Batten Disease Treatment, by Disease Type USD Million (2020-2025)
  • Table 250. United States Batten Disease Treatment, by Route of Administration USD Million (2020-2025)
  • Table 251. United States Batten Disease Treatment, by Therapy Type USD Million (2020-2025)
  • Table 252. United States Batten Disease Treatment, by End-Users USD Million (2020-2025)
  • Table 253. Canada Batten Disease Treatment, by Disease Type USD Million (2020-2025)
  • Table 254. Canada Batten Disease Treatment, by Route of Administration USD Million (2020-2025)
  • Table 255. Canada Batten Disease Treatment, by Therapy Type USD Million (2020-2025)
  • Table 256. Canada Batten Disease Treatment, by End-Users USD Million (2020-2025)
  • Table 257. Mexico Batten Disease Treatment, by Disease Type USD Million (2020-2025)
  • Table 258. Mexico Batten Disease Treatment, by Route of Administration USD Million (2020-2025)
  • Table 259. Mexico Batten Disease Treatment, by Therapy Type USD Million (2020-2025)
  • Table 260. Mexico Batten Disease Treatment, by End-Users USD Million (2020-2025)
  • Table 261. Research Programs/Design for This Report
  • Table 262. Key Data Information from Secondary Sources
  • Table 263. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Batten Disease Treatment: by Disease Type USD Million (2014-2019)
  • Figure 5. Global Batten Disease Treatment: by Route of Administration USD Million (2014-2019)
  • Figure 6. Global Batten Disease Treatment: by Therapy Type USD Million (2014-2019)
  • Figure 7. Global Batten Disease Treatment: by End-Users USD Million (2014-2019)
  • Figure 8. South America Batten Disease Treatment Share (%), by Country
  • Figure 9. Asia Pacific Batten Disease Treatment Share (%), by Country
  • Figure 10. Europe Batten Disease Treatment Share (%), by Country
  • Figure 11. MEA Batten Disease Treatment Share (%), by Country
  • Figure 12. North America Batten Disease Treatment Share (%), by Country
  • Figure 13. Global Batten Disease Treatment share by Players 2019 (%)
  • Figure 14. Global Batten Disease Treatment share by Players (Top 3) 2019(%)
  • Figure 15. Global Batten Disease Treatment share by Players (Top 5) 2019(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. BioMarin Pharmaceutical Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. BioMarin Pharmaceutical Inc. (United States) Revenue: by Geography 2019
  • Figure 19. Seneb BioSciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Seneb BioSciences, Inc. (United States) Revenue: by Geography 2019
  • Figure 21. ReGenX Biosciences LLC (United States) Revenue, Net Income and Gross profit
  • Figure 22. ReGenX Biosciences LLC (United States) Revenue: by Geography 2019
  • Figure 23. Amicus Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 24. Amicus Therapeutics (United States) Revenue: by Geography 2019
  • Figure 25. Ionis Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Ionis Pharmaceuticals, Inc. (United States) Revenue: by Geography 2019
  • Figure 27. Celenex, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Celenex, Inc. (United States) Revenue: by Geography 2019
  • Figure 29. Pfizer Inc (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer Inc (United States) Revenue: by Geography 2019
  • Figure 31. Polaryx Therapeutics, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 32. Polaryx Therapeutics, Inc (United States) Revenue: by Geography 2019
  • Figure 33. Abeona Therapeutics Inc (United States) Revenue, Net Income and Gross profit
  • Figure 34. Abeona Therapeutics Inc (United States) Revenue: by Geography 2019
  • Figure 35. Evotec SE (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Evotec SE (Germany) Revenue: by Geography 2019
  • Figure 37. Global Batten Disease Treatment: by Disease Type USD Million (2020-2025)
  • Figure 38. Global Batten Disease Treatment: by Route of Administration USD Million (2020-2025)
  • Figure 39. Global Batten Disease Treatment: by Therapy Type USD Million (2020-2025)
  • Figure 40. Global Batten Disease Treatment: by End-Users USD Million (2020-2025)
  • Figure 41. South America Batten Disease Treatment Share (%), by Country
  • Figure 42. Asia Pacific Batten Disease Treatment Share (%), by Country
  • Figure 43. Europe Batten Disease Treatment Share (%), by Country
  • Figure 44. MEA Batten Disease Treatment Share (%), by Country
  • Figure 45. North America Batten Disease Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • BioMarin Pharmaceutical Inc. (United States)
  • Seneb BioSciences, Inc. (United States)
  • ReGenX Biosciences LLC (United States)
  • Amicus Therapeutics (United States)
  • Ionis Pharmaceuticals, Inc. (United States)
  • Celenex, Inc. (United States)
  • Pfizer Inc (United States)
  • Polaryx Therapeutics, Inc (United States)
  • Abeona Therapeutics Inc (United States)
  • Evotec SE (Germany)
Additional players considered in the study are as follows:
Spark Therapeutics, Inc (United States) , Regenxbio Inc (United States) , BioMarin Pharmaceutical Inc. (United States) , STEMCELL Technologies Inc. (Canada) , Neurogene Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation